COLUMBUS, Ohio – The team of neurologists and neurosurgeons at The Ohio State University Wexner Medical Center and its Neurological Institute are among the first in the nation to implant a new deep-brain stimulation (DBS) device that will help improve the quality of life of patients with Parkinson’s disease.
A team at Washington University in St. Louis has developed a new brain stimulation technique using focused ultrasound that is able to turn specific types of neurons in the brain on and off and precisely control motor activity without surgical device implantation.
First-of-its kind technology allows Rush doctors to remotely deliver a digital prescription for patients with brain stimulation therapy for Parkinson’s Disease and Essential Tremor.
The Parkinson’s Disease and Movement Disorder Center at Henry Ford Health System was the first in the United States to offer a new FDA-approved device to help treat the symptoms of Parkinson’s disease. Neurosurgeon Jason Schwalb, M.D. surgically implanted the Vercise Genus™ Deep Brain Stimulation (DBS) System, which stimulates a targeted region of the brain through implanted leads that are placed in the brain.
Dopamine and serotonin are at work at sub-second speeds to shape how people perceive the world and take action based on their perception. The discovery shows researchers can simultaneously measure the activity of both dopamine and serotonin in disorders ranging from depression to Parkinson’s disease.
A team of researchers in the United States and Japan reports that spinal cord stimulation (SCS) measurably decreased pain and reduced motor symptoms of Parkinson’s disease, both as a singular therapy and as a “salvage therapy” after deep brain stimulation (DBS) therapies were ineffective.
There’s good news for people with Parkinson’s disease. A new study shows that deep brain stimulation may not increase the risk of developing dementia. The study is published in the July 1, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.